• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CRS 和 HIPEC 术后早期并发症的再次手术:适应证、时机、手术过程和结果。

Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome.

机构信息

Department of General and Visceral Surgery, Krankenhaus Barmherzige Brüder, Prüfeninger Strasse 86, 93049, Regensburg, Germany.

Department of Informatics, University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.

出版信息

Langenbecks Arch Surg. 2019 Aug;404(5):541-546. doi: 10.1007/s00423-019-01808-8. Epub 2019 Jul 27.

DOI:10.1007/s00423-019-01808-8
PMID:31352505
Abstract

PURPOSE

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become standard of care for many peritoneal malignancies in selected patients. Nevertheless, this aggressive treatment strategy is associated with significant major morbidity. The aim of the present study is to analyze the re-operation rate and clinical outcome following CRS and HIPEC.

PATIENTS AND METHODS

In the present study, prospectively documented data of 474 consecutive patients treated with CRS and HIPEC between February 2011 and December 2015 in a high-volume certified reference center for peritoneal malignancies in Germany have been retrospectively analyzed.

RESULTS

The re-operation rate was 14.5%. The most frequent reasons for revisional surgery were fascial dehiscence, intraabdominal hemorrhage, and anastomotic leak. Most complications occurred between postoperative day 7 and 9. However, postoperative bleeding was more common within the first 5 days after surgery. The overall in-hospital mortality rate was 2.1% for all patients and 10% after revisional surgery.

CONCLUSIONS

CRS and HIPEC are associated with an acceptable re-operation rate and low mortality rate. Most frequently, re-operations are performed on 7-9 days after initial surgery due to fascial dehiscence, pancreatitis, or anastomotic leak. Postoperative bleedings are more common within the first 5 days after surgery.

摘要

目的

细胞减灭术(CRS)和腹腔内热灌注化疗(HIPEC)已成为许多选定患者腹膜恶性肿瘤的标准治疗方法。然而,这种积极的治疗策略与显著的主要发病率相关。本研究旨在分析 CRS 和 HIPEC 后的再手术率和临床结果。

患者和方法

本研究回顾性分析了 2011 年 2 月至 2015 年 12 月期间在德国一家腹膜恶性肿瘤的大容量认证参考中心接受 CRS 和 HIPEC 治疗的 474 例连续患者的前瞻性记录数据。

结果

再手术率为 14.5%。再次手术最常见的原因是筋膜裂开、腹腔内出血和吻合口漏。大多数并发症发生在术后第 7-9 天。然而,术后出血更常见于手术后的前 5 天。所有患者的总住院死亡率为 2.1%,再次手术后为 10%。

结论

CRS 和 HIPEC 相关的再手术率和死亡率可接受。最常见的是在初次手术后的 7-9 天因筋膜裂开、胰腺炎或吻合口漏而进行再次手术。术后出血更常见于手术后的前 5 天。

相似文献

1
Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome.CRS 和 HIPEC 术后早期并发症的再次手术:适应证、时机、手术过程和结果。
Langenbecks Arch Surg. 2019 Aug;404(5):541-546. doi: 10.1007/s00423-019-01808-8. Epub 2019 Jul 27.
2
Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.出院后接受减瘤手术加腹腔热灌注化疗患者主要并发症的延迟出现
J Surg Oncol. 2015 Mar;111(3):324-7. doi: 10.1002/jso.23834. Epub 2014 Dec 31.
3
Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.复发性腹膜癌患者的重复细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)
World J Surg Oncol. 2016 Feb 24;14(1):42. doi: 10.1186/s12957-016-0804-x.
4
Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.细胞减灭术和腹腔内热化疗后腹膜恶性肿瘤患者的肠皮肤瘘:发病率、管理及结局
Surg Oncol. 2016 Sep;25(3):315-20. doi: 10.1016/j.suronc.2016.05.025. Epub 2016 May 24.
5
A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.一种用于预测减瘤手术联合热灌注腹腔化疗后主要并发症的新型工具。
Ann Surg Oncol. 2016 May;23(5):1609-17. doi: 10.1245/s10434-015-5012-3. Epub 2015 Dec 17.
6
Prognostic Factors and Significance of Gastrointestinal Leak After Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC).减瘤手术(CRS)联合腹腔热灌注化疗(HIPEC)后胃肠道漏的预后因素及意义
Ann Surg Oncol. 2017 Apr;24(4):890-897. doi: 10.1245/s10434-016-5738-6. Epub 2016 Dec 19.
7
Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.脾切除术会增加肿瘤细胞减灭术和腹腔内热灌注化疗术后的并发症。
Ann Surg Oncol. 2016 Jun;23(6):1980-5. doi: 10.1245/s10434-016-5147-x. Epub 2016 Feb 25.
8
High-grade complication is associated with poor overall survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.高级别并发症与细胞减灭术和腹腔内热灌注化疗后的总体生存不良相关。
Int J Clin Oncol. 2020 May;25(5):984-994. doi: 10.1007/s10147-019-01609-5. Epub 2020 Jan 8.
9
Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.在完全细胞减灭术(CRS)联合术中热灌注化疗(HIPEC)期间进行术中系统性细菌采样是否会影响术后治疗?一种术后腹部感染并发症的新预测因素。
World J Surg. 2016 Dec;40(12):3035-3043. doi: 10.1007/s00268-016-3635-6.
10
Treatment-Related Mortality After Cytoreductive Surgery and HIPEC in Patients with Colorectal Peritoneal Carcinomatosis is Underestimated by Conventional Parameters.传统参数低估了结直肠癌腹膜转移患者接受细胞减灭术和腹腔热灌注化疗后的治疗相关死亡率。
Ann Surg Oncol. 2016 Jan;23(1):99-105. doi: 10.1245/s10434-015-4699-5. Epub 2015 Jul 7.

引用本文的文献

1
Complications and Mortality Rate of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: Italian Peritoneal Surface Malignancies Oncoteam Results Analysis.减瘤手术联合热灌注腹腔化疗的并发症及死亡率:意大利腹膜表面恶性肿瘤肿瘤治疗团队结果分析
Cancers (Basel). 2022 Nov 25;14(23):5824. doi: 10.3390/cancers14235824.
2
Management of peritoneal surface metastases from colorectal cancer: Cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, pressurized intraperitoneal chemotherapy, and beyond.结直肠癌腹膜表面转移的管理:细胞减灭术、腹腔内热灌注化疗、腹腔加压化疗及其他。
Front Oncol. 2022 Nov 8;12:992030. doi: 10.3389/fonc.2022.992030. eCollection 2022.
3

本文引用的文献

1
Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.挪威结直肠癌腹膜转移的完全细胞减灭术和腹腔热灌注化疗:全国患者队列中的预后因素和肿瘤学结局
J Surg Oncol. 2016 Aug;114(2):222-7. doi: 10.1002/jso.24290. Epub 2016 May 12.
2
Hyperthermic intraperitoneal chemoperfusion with high dose oxaliplatin: Influence of perfusion temperature on postoperative outcome and survival.高剂量奥沙利铂腹腔热灌注化疗:灌注温度对术后结局和生存的影响。
F1000Res. 2013 Sep 3;2:179. doi: 10.12688/f1000research.2-179.v2. eCollection 2013.
3
Extraperitoneal Approach During Peritonectomy in the Right Upper Quadrant for Peritoneal Metastases from Ovarian Malignancies.
右上象限腹膜切除术治疗卵巢恶性肿瘤腹膜转移的腹膜外入路。
In Vivo. 2022 Jan-Feb;36(1):341-349. doi: 10.21873/invivo.12708.
4
In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany.德国接受腹腔内热灌注化疗治疗腹膜表面恶性肿瘤患者的住院死亡率和并发症发生率与健康保险数据相关。
Ann Surg Oncol. 2021 Jul;28(7):3823-3830. doi: 10.1245/s10434-020-09301-z. Epub 2020 Nov 9.
5
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: Learning Curve Based on Surgical and Oncological Outcomes.腹膜表面恶性肿瘤的细胞减灭术及腹腔内热灌注化疗:基于手术及肿瘤学结局的学习曲线
Cancers (Basel). 2020 Aug 23;12(9):2387. doi: 10.3390/cancers12092387.
The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.
1200例腹膜恶性肿瘤患者的减瘤手术及腹腔热灌注化疗结果
Colorectal Dis. 2015 Sep;17(9):772-8. doi: 10.1111/codi.12975.
4
A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.有或无术中腹腔热灌注化疗的手术后胰瘘的对比分析
Ann Surg Oncol. 2015 May;22(5):1651-7. doi: 10.1245/s10434-014-4186-4. Epub 2014 Oct 28.
5
Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.胰体尾切除术对接受细胞减灭术和腹腔热灌注化疗治疗的腹膜表面疾病预后的影响。
Ann Surg Oncol. 2015 May;22(5):1645-50. doi: 10.1245/s10434-014-3976-z. Epub 2014 Aug 14.
6
Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.阑尾癌腹膜转移行细胞减灭术联合热灌注化疗后的生存预测及预后因素
Ann Surg Oncol. 2014 Dec;21(13):4218-25. doi: 10.1245/s10434-014-3869-1. Epub 2014 Jul 2.
7
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience.细胞减灭术及热灌注化疗用于复发性上皮性卵巢癌伴腹膜转移:单中心经验
Langenbecks Arch Surg. 2014 Jun;399(5):589-94. doi: 10.1007/s00423-014-1207-5. Epub 2014 May 11.
8
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.细胞减灭术和腹腔热灌注化疗治疗腹膜癌转移:来自一家三级医疗机构的结果。
J Gastrointest Surg. 2014 May;18(5):1024-31. doi: 10.1007/s11605-014-2477-5. Epub 2014 Feb 28.
9
Surgical outcomes of hyperthermic intraperitoneal chemotherapy: analysis of the american college of surgeons national surgical quality improvement program.腹腔内热灌注化疗的手术效果:美国外科医师学会国家手术质量改进计划分析。
JAMA Surg. 2014 Feb;149(2):170-5. doi: 10.1001/jamasurg.2013.3640.
10
Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan.在日本的一家机构中,细胞减灭术和腹腔内热化疗的发病率和死亡率结果。
Gastroenterol Res Pract. 2012;2012:836425. doi: 10.1155/2012/836425. Epub 2012 Jun 18.